Skip to main content
Listen in: the latest news on GLP-1s! Listen to our new Coffee with ClearScript for the latest news on GLP-1s!

The clear choice in pharmacy benefit management.

Insights Archive

April 3, 2024

Rezdiffra (resmetirom)

On March 14, 2024, drug manufacturer Madrigal Pharmaceuticals announced the approval of Rezdiffra™, a new, first in class oral therapy for nonalcoholic steatohepatitis (NASH). This disease, which impacts an estimated 6-8 million people in the U.S., is underdiagnosed and if left untreated, it can cause serious liver complications. Read more about this approval and its implications.

Biosimilars syringe bottle and syringe

April 3, 2024

Understanding Biosimilar Basics

With Humira® biosimilars expected to have a significant impact in 2024, some ClearScript clients are asking for more information. Here we provide the biosimilar basics and what their increasing presence in the marketplace means to the pharmacy benefit.

Looking down at a counter with scattered medications and a stethoscope as the "0" in the word 2024.

January 11, 2024

Navigating 2024: Three topics shaping the pharmacy benefit

As we reflect on the developments of 2023 and set our sights on 2024, the pharmacy benefit landscape is undergoing significant transformations. Read on to learn what ClearScript is watching in this evolving and complex field to stay ahead of changes that will impact the pharmacy benefit.

September 29, 2023

Insulin Update

Amidst growing public and government attention on insulin affordability, what do plan sponsors need to know as they plan coverage strategies in 2024 and beyond?